INSIGHTS ON CLINICAL TRIAL DESIGN

• Déjà vu? A Decade At AAIC, And The Endpoints Haven't Moved

  Cognitive endpoints in Alzheimer's trials haven't kept pace with the shift to earlier-stage treatment. Modern trials need tools built to catch subtle change.

• Improving Rare Disease Recruitment With Data And AI

  Finding patients for rare disease clinical trials can be an uphill battle; fortunately, there are ways sponsors can address the most common stumbling blocks in the recruitment process.

• AI's Bottleneck In Clinical Trials Moved, And Most People Missed It

  AI has accelerated drug discovery, but the real bottleneck is now clinical trial operations. Explore why regulatory success depends on auditable data governance, not model speed.

• Navigating Tension Of Clinical Equipoise In Precision Oncology Trials

  This roundtable discussion examines the tension between legacy methods and modern innovation, exploring the complexities of hybrid trial designs and the changing regulatory landscape.

   

• Why Are Sponsors Prioritizing Ophthalmology Clinical Trials?

  3/18/2026

  Explore how demographic shifts and retinal innovation are transforming ophthalmology trials, and why operational precision is the key to protecting data integrity in this high-growth sector.

• Accelerate Your Oncology Breakthroughs

  4/16/2025

  Finding the right partnership can help your oncology clinical trials overcome trial complexities through strategic planning, a deep scientific understanding, and operational excellence.

• GA Screening: Early Detection For Future Trial Recruitment

  4/9/2026

  Community-based screenings identify undiagnosed eye disease at high rates, creating a scalable, high-trust pathway for early intervention and improved clinical research recruitment.

• Patient Centric Clinical Trials: Why Transportation Is A Timeline Risk

  2/24/2026

  Address transportation barriers to reduce protocol deviations and data gaps. Strategies that lower travel burden protect study timelines and improve visit adherence for better trial outcomes.

• Early Immune Profiling With In Vivo, In Vitro, And Ex Vivo Systems

  10/7/2025

  Modern biologics increasingly interact with the immune system. While these innovations enable transformative therapies, they can also provoke acute immune activation during first-in-human (FIH) trials.